# OnCo record ronan-kelly (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ronan-kelly/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ronan-kelly" ;
  schema:name "Ronan J. Kelly"@en ;
  schema:description "Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease."@en ;
  schema:url <https://onco.cc/people/ronan-kelly/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab> ;
  onco:tag "esophageal", "immunotherapy", "adjuvant" ;
  schema:jobTitle "Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas" ;
  schema:sameAs <https://orcid.org/0000-0002-6446-2103> ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:institutions <https://onco.cc/institutions/baylor-sammons-dallas/> ;
  onco:trials <https://onco.cc/trials/checkmate-577/> ;
  onco:journals <https://onco.cc/journals/jnccn/> ;
  schema:affiliation <https://onco.cc/institutions/baylor-sammons-dallas/> .